N/A
Completed N=100
Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®
Second Degree Burn
Source: ClinicalTrials.gov NCT00742183 ↗
Enrolled (actual)
100
Serious AEs
3.0%
Results posted
Nov 2010
Primary outcomePrimary: Compare the Costs of Using the Interventions (Direct and Indirect) — 395.03; 775.79 dollars
Summary
The primary objective is to compare the incremental costs (direct and indirect) and benefits (healing outcomes, quality of life) of using foam silver dressing (Mepilex® Ag) to a Silver sulfadiazine 1% cream (Silvadene®) from the perspective of the health care provider.
The secondary objectives are to investigate the safety, the tolerance and the performance on burn status including pain.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Compare the Costs of Using the Interventions (Direct and Indirect) |
395.03; 775.79 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with a second degree burn covering 5% to 20% BSA. TBSA covered with burn is allowed to be up to 25%, allowing a maximum of 10% to be third degree burn (only the Second degree burn should be treated)
- Burn of thermal origin
- Both gender with an age ≥ 5 years at randomization
- Signed informed consent
- Subjects who are younger than the legal consenting age must have a legally authorized representative
Exclusion Criteria
- - Burns equal to or older than 36 hours
- Burns of chemical and electrical origin
- Clinically infected Burn (as judged by the investigator)
- Treatment of the burn with an active agent before study entry, SSD is allowed up to 24 hours prior to randomization
- Patients with necrotising leucocytic vasculitis or pyoderma gangrenosa.
- Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe anaemia) judged by the investigator to be a potential interference in the treatment.
- Patients with insulin dependent diabetes mellitus
- Patients treated with systemic glucocorticosteroids, except patients taking occasional doses or doses less than 10mg prednisolon/day or equivalent.
- Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days.
- Known allergy/hypersensitivity to any of the components of the investigation products.
- Patients with physical and/or mental conditions that are not expected to comply with the investigation.
- Participation in other clinical investigation(s) within 1 month prior to start of the investigation
- Pregnancy
- Previously randomised to this investigation
Data sourced from ClinicalTrials.gov (NCT00742183). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.